XM does not provide services to residents of the United States of America.

XM does not provide services to residents of the United States of America.
V
V

Vertex

News

Reuters - 3 weeks ago

Beam Therapeutics falls after patient death in early trial

BUZZ-Beam Therapeutics falls after patient death in early trial ** Shares of biotech firm Beam Therapeutics BEAM.O fall 3.30% to $23.56 ** A patient with sickle cell disease has died due to respiratory failure in an early-to-mid stage trial of company's CRISPR-based cell therapy, BEAM-101, according to an abstract ** Respiratory failure was likely
V
Reuters - 3 weeks ago

Vertex Pharmaceuticals Inc reports results for the quarter ended in September 30 - Earnings Summary

Vertex Pharmaceuticals Inc reports results for the quarter ended in September 30 - Earnings Summary Vertex Pharmaceuticals Inc VRTX.OQ reported quarterly adjusted earnings of $4.38​​ per share for the quarter ended September 30, higher than the same quarter last year, when the company reported EPS of $4.08. The mean expectation of twenty nine analysts for the quarter was for earnings of $4.14 per share.
V
Reuters - 3 weeks ago

U.S. Celanese Corporation, Disc Medicine, Editas Medicine

U.S. RESEARCH ROUNDUP-Celanese Corporation, Disc Medicine, Editas Medicine Nov 5 (Reuters) - Wall Street securities analysts revised their ratings and price targets on several U.S.-listed companies, including Celanese Corporation, Disc Medicine and Editas Medicine, on Tuesday. HIGHLIGHTS * Affiliated Managers Group Inc AMG.N : TD Cowen cuts to hold from buy * Celanese Corporation CE.N : Wells Fargo cuts to equal weight from overweight * Disc Medicine Inc IRON.O : Raymond James raises to strong b
A
A
B
C
C
E
H
I
M
V
W
E
F
B
C
Reuters - 3 weeks ago

Vertex Pharmaceuticals Q3 Operating Income USD 1,116.3 Million

BRIEF-Vertex Pharmaceuticals Q3 Operating Income USD 1,116.3 Million Nov 04 (Reuters) - Vertex Pharmaceuticals Q3 net income USD 1,045.4 million. Q3 revenue USD 2,771.9 million vs. IBES estimate USD 2,724 million outlook FY product revenue USD 10,800-10,900 million
V
Reuters - 3 weeks ago

Vertex Pharma lifts annual revenue forecast on cystic fibrosis treatments strength

Vertex Pharma lifts annual revenue forecast on cystic fibrosis treatments strength Nov 4 (Reuters) - Vertex Pharmaceuticals VRTX.O raised its annual revenue forecast on Monday after it beat third-quarter estimates on demand for its cystic fibrosis (CF) treatments. The drugmaker now expects 2024 product revenue between $10.8 billion and $10.9 billion compared to its prior expectations of $10.65 billion to $10.85 billion.
V
Reuters - 3 weeks ago

What to Watch in the Week Ahead and on Monday, November 4

What to Watch in the Week Ahead and on Monday, November 4 The Day Ahead is an email and PDF publication that includes the day's major stories and events, analyses and other features. To receive The Day Ahead, Eikon users can register at DAY/US . Thomson One users can register at RT/DAY/US. All times in ET/GMT ON MONDAY On the U.S. economic front, the Commerce Department's Census Bureau is set to show that factory orders likely dropped 0.4% in September after falling 0.2% in August.
H
Q
S
V
T
L
U
Reuters - 4 weeks ago

U.S. Agilon Health, Alphabet, Crocs

U.S. RESEARCH ROUNDUP-Agilon Health, Alphabet, Crocs Oct 30 (Reuters) - Wall Street securities analysts revised their ratings and price targets on several U.S.-listed companies, including Agilon Health, Alphabet and Crocs, on Wednesday. HIGHLIGHTS * Agilon Health Inc AGL.N : Citigroup cuts to sell from neutral * Alphabet Inc GOOGL.O : Seaport Research Partners raises to buy from neutral * Crocs Inc CROX.O : Raymond James cuts to market perform from outperform * Leggett & Platt Inc LEG.N : Piper
A
B
C
G
I
M
Q
V
V
A
E
E
S
U
A
A
F
L
R
Reuters - 1 month ago

Biotech M&A to show less 'fire power' in 2024 due to low-valued deals

LIVE MARKETS-Biotech M&A to show less 'fire power' in 2024 due to low-valued deals Main U.S. indexes red; Dow off most, down ~0.8% Real Estate weakest S&P sector; Tech sole gainer Dollar up; crude gains ~2%; gold ~flat; bitcoin down ~2.5% U.S. 10-Year Treasury yield jumps to ~4.18% Welcome to the home for real-time coverage of markets brought to you by Reuters reporters.
A
A
B
G
P
V
U
U
Reuters - 1 month ago

Nasdaq top and bottom performing stocks at about 03:45 p.m. EDT

BUZZ - Nasdaq top and bottom performing stocks at about 03:45 p.m. EDT Nasdaq 100 .NDX Top Performers Percent Change Broadcom Inc AVGO.OQ +2.9% Micron Technology Inc MU.OQ +2.8% ASML Holding NV ASML.OQ +2.6% Vertex Pharmaceuticals Inc VRTX.OQ +2.1% Arm Holdings PLC ARM.OQ +1.8% Bottom Performers Percent Change CSX Corp CSX.OQ -6.4% Moderna Inc MRNA.OQ -4.0% Warner Bros Discovery Inc WBD.OQ -3.6% PDD Holdings Inc PDD.OQ -3.2% Lululemon Athletica Inc LULU.OQ -3.2% The Nasdaq 100 .NDX gained 38.10
B
C
L
M
V
A
U
P
Reuters - 2 months ago

Why gene therapy for sickle cell is slow to catch on with patients

INSIGHT-Why gene therapy for sickle cell is slow to catch on with patients By Deena Beasley LOS ANGELES, Sept 28 (Reuters) - Student Zoe Davis, 20, was just weeks into her junior year when she landed back in the hospital with severe sickle cell pain earlier this month. She is doing what she can to prevent the crippling attacks in her arms, legs and abdomen that are becoming more frequent.
N
P
V
Reuters - 2 months ago

Pfizer's Oxbryta exit may hasten trials of rival experimental sickle cell drugs, analysts say

UPDATE 1-Pfizer's Oxbryta exit may hasten trials of rival experimental sickle cell drugs, analysts say EMA raises concerns about deaths in Oxbryta trials Shares of Agios and Fulcrum rise after Pfizer's decision Adds FDA statement in paragraph 4 By Kashish Tandon and Christy Santhosh Sept 26 (Reuters) - Pfizer's PFE.N decision late on Wednesday to withdraw its sickle cell disease treatment due to the risk of death could help speed up trials of new experimental rivals, Wall Street analysts said.
N
P
V
Reuters - 2 months ago

Pfizer's Oxbryta exit may hasten trials of rival experimental sickle cell drugs, analysts say

Pfizer's Oxbryta exit may hasten trials of rival experimental sickle cell drugs, analysts say EMA raises concerns about deaths in Oxbryta trials Shares of Agios and Fulcrum rise after Pfizer's decision By Kashish Tandon and Christy Santhosh Sept 26 (Reuters) - Pfizer's PFE.N decision late on Wednesday to withdraw its sickle cell disease treatment due to the risk of death could help speed up trials of new experimental rivals, Wall Street analysts said.
N
P
V
Reuters - 2 months ago

Health Canada Grants Marketing Authorization Of First Crispr/Cas9 Gene-Edited Therapy, Casgevy® (Exagamglogene Autotemcel), For The Treatment Of Sickle Cell Disease And Transfusion-Dependent Beta Thalassemia

BRIEF-Health Canada Grants Marketing Authorization Of First Crispr/Cas9 Gene-Edited Therapy, Casgevy® (Exagamglogene Autotemcel), For The Treatment Of Sickle Cell Disease And Transfusion-Dependent Beta Thalassemia Vertex Pharmaceuticals Inc VRTX.O : HEALTH CANADA GRANTS MARKETING AUTHORIZATION OF FIRST CRISPR/CAS9 GENE-EDITED THERAPY, CASGEVY® (E
V
Reuters - 2 months ago

Bluebird bio to cut 25% of jobs in fresh bid to battle cash crunch

UPDATE 2-Bluebird bio to cut 25% of jobs in fresh bid to battle cash crunch Adds CEO statement in paragraph 5, background throughout Sept 24 (Reuters) - Bluebird bio BLUE.O will lay off about 25% of its workforce, or 95 employees, the gene therapy maker said on Tuesday, in a second major restructuring in two years as the company focuses on launching its treatments amid a cash crunch.
V
Reuters - 3 months ago

Nasdaq top and bottom performing stocks at about 03:45 p.m. EDT

BUZZ - Nasdaq top and bottom performing stocks at about 03:45 p.m. EDT Nasdaq 100 .NDX Top Performers Percent Change Dollar Tree Inc DLTR.OQ +7.2% Tesla Inc TSLA.OQ +4.3% Zscaler Inc ZS.OQ +3.1% Comcast Corp CMCSA.OQ +2.7% Amazon.com Inc AMZN.OQ +2.3% Bottom Performers Percent Change Copart Inc CPRT.OQ -6.6% Old Dominion Freight Line Inc ODFL.OQ -5.4% AstraZeneca PLC AZN.OQ -3.4% Super Micro Computer Inc SMCI.OQ -3.1% Vertex Pharmaceuticals Inc VRTX.OQ -2.6% The Nasdaq 100 .NDX lost 36.77 points
A
A
C
T
V
D
U
C
O
Reuters - 3 months ago

Nasdaq top and bottom performing stocks at about 12:01 p.m. EDT

BUZZ - Nasdaq top and bottom performing stocks at about 12:01 p.m. EDT Nasdaq 100 .NDX Top Performers Percent Change Tesla Inc TSLA.OQ +3.2% Dollar Tree Inc DLTR.OQ +2.3% Amazon.com Inc AMZN.OQ +2.1% Comcast Corp CMCSA.OQ +1.6% Arm Holdings PLC ARM.OQ +1.2% Bottom Performers Percent Change Copart Inc CPRT.OQ -7.1% Old Dominion Freight Line Inc ODFL.OQ -6.8% AstraZeneca PLC AZN.OQ -3.5% Vertex Pharmaceuticals Inc VRTX.OQ -3.1% Regeneron Pharmaceuticals Inc REGN.OQ -3.0% The Nasdaq 100 .NDX lost 9
A
A
C
R
T
V
D
U
C
O
Reuters - 3 months ago

Nasdaq top and bottom performing stocks at about 12:01 p.m. EDT

BUZZ - Nasdaq top and bottom performing stocks at about 12:01 p.m. EDT Nasdaq 100 .NDX Top Performers Percent Change Gilead Sciences Inc GILD.OQ +2.0% Vertex Pharmaceuticals Inc VRTX.OQ +1.8% Copart Inc CPRT.OQ +1.2% Verisk Analytics Inc VRSK.OQ +1.2% Old Dominion Freight Line Inc ODFL.OQ +1.1% Bottom Performers Percent Change Super Micro Computer Inc SMCI.OQ -25.1% PDD Holdings Inc PDD.OQ -6.3% Arm Holdings PLC ARM.OQ -5.5% Lululemon Athletica Inc LULU.OQ -4.4% Micron Technology Inc MU.OQ -4.3%
G
L
M
V
V
U
P
C
O

Conditions

Popular Assets

Disclaimer: The XM Group entities provide execution-only service and access to our Online Trading Facility, permitting a person to view and/or use the content available on or via the website, is not intended to change or expand on this, nor does it change or expand on this. Such access and use are always subject to: (i) Terms and Conditions; (ii) Risk Warnings; and (iii) Full Disclaimer. Such content is therefore provided as no more than general information. Particularly, please be aware that the contents of our Online Trading Facility are neither a solicitation, nor an offer to enter any transactions on the financial markets. Trading on any financial market involves a significant level of risk to your capital.

All material published on our Online Trading Facility is intended for educational/informational purposes only, and does not contain – nor should it be considered as containing – financial, investment tax or trading advice and recommendations; or a record of our trading prices; or an offer of, or solicitation for, a transaction in any financial instruments; or unsolicited financial promotions to you.

Any third-party content, as well as content prepared by XM, such as: opinions, news, research, analyses, prices and other information or links to third-party sites contained on this website are provided on an “as-is” basis, as general market commentary, and do not constitute investment advice. To the extent that any content is construed as investment research, you must note and accept that the content was not intended to and has not been prepared in accordance with legal requirements designed to promote the independence of investment research and as such, it would be considered as marketing communication under the relevant laws and regulations. Please ensure that you have read and understood our Notification on Non-Independent Investment. Research and Risk Warning concerning the foregoing information, which can be accessed here.

Risk Warning: Your capital is at risk. Leveraged products may not be suitable for everyone. Please consider our Risk Disclosure.